BRPI0809996B8 - compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas - Google Patents

compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas

Info

Publication number
BRPI0809996B8
BRPI0809996B8 BRPI0809996A BRPI0809996A BRPI0809996B8 BR PI0809996 B8 BRPI0809996 B8 BR PI0809996B8 BR PI0809996 A BRPI0809996 A BR PI0809996A BR PI0809996 A BRPI0809996 A BR PI0809996A BR PI0809996 B8 BRPI0809996 B8 BR PI0809996B8
Authority
BR
Brazil
Prior art keywords
compounds
alopecia
diabetes
stroke
viral
Prior art date
Application number
BRPI0809996A
Other languages
English (en)
Portuguese (pt)
Inventor
Atrash Butrus
Mcdonald Edward
William Sheldrake Peter
Frame Sheelagh
Green Simon
Original Assignee
Cyclacel Ltd
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd, Cancer Research Tech Ltd filed Critical Cyclacel Ltd
Publication of BRPI0809996A2 publication Critical patent/BRPI0809996A2/pt
Publication of BRPI0809996B1 publication Critical patent/BRPI0809996B1/pt
Publication of BRPI0809996B8 publication Critical patent/BRPI0809996B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
BRPI0809996A 2007-04-04 2008-04-02 compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas BRPI0809996B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92189707P 2007-04-04 2007-04-04
GBGB0706632.7A GB0706632D0 (en) 2007-04-04 2007-04-04 New purine derivatives
US60/921,897 2007-04-04
GB0706632.7 2007-04-04
PCT/GB2008/001173 WO2008122767A2 (en) 2007-04-04 2008-04-02 2, 6, 9-substituted purine derivatives having anti proliferative properties

Publications (3)

Publication Number Publication Date
BRPI0809996A2 BRPI0809996A2 (pt) 2014-10-14
BRPI0809996B1 BRPI0809996B1 (pt) 2019-09-03
BRPI0809996B8 true BRPI0809996B8 (pt) 2021-05-25

Family

ID=38090893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809996A BRPI0809996B8 (pt) 2007-04-04 2008-04-02 compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas

Country Status (13)

Country Link
US (1) US8592581B2 (https=)
EP (1) EP2139893B1 (https=)
JP (1) JP5466145B2 (https=)
CN (1) CN101679434B (https=)
AU (1) AU2008235361B2 (https=)
BR (1) BRPI0809996B8 (https=)
CA (1) CA2681529C (https=)
ES (1) ES2427845T3 (https=)
GB (1) GB0706632D0 (https=)
MX (1) MX2009010660A (https=)
PL (1) PL2139893T3 (https=)
RU (1) RU2461559C2 (https=)
WO (1) WO2008122767A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0903346D0 (en) 2009-02-27 2009-04-08 Cambridge Advanced Tech Transgenic Plants
GB201001075D0 (en) * 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
CA2973949C (en) 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
US11340215B2 (en) 2016-02-26 2022-05-24 Japanese Foundation For Cancer Research Screening method of anticancer agent focused on function of HP1 and evaluation system
KR102524773B1 (ko) * 2017-01-26 2023-04-21 싸이클라셀 리미티드 퓨린 유도체의 제조 방법
EP3388432A1 (en) 2017-04-10 2018-10-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders
CR20210287A (es) 2018-11-01 2022-02-15 Syros Pharmaceuticals Inc Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
RU2754441C2 (ru) * 2019-12-30 2021-09-02 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
GB202000901D0 (en) 2020-01-22 2020-03-04 Cyclacel Ltd Process
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers
US20240247001A1 (en) 2022-12-16 2024-07-25 Astrazeneca Ab 2,6,9-trisubstituted purines
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
HK1044334A1 (zh) * 1999-02-01 2002-10-18 Cv治疗公司 依赖细胞周期蛋白的激酶2和IκB-α的嘌呤抑制剂
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
DE60205376T2 (de) * 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6812232B2 (en) * 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US20080125404A1 (en) * 2004-08-27 2008-05-29 Cyclacel Limited Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination

Also Published As

Publication number Publication date
CA2681529A1 (en) 2008-10-16
AU2008235361A1 (en) 2008-10-16
JP2010523534A (ja) 2010-07-15
BRPI0809996B1 (pt) 2019-09-03
ES2427845T3 (es) 2013-11-04
CN101679434A (zh) 2010-03-24
BRPI0809996A2 (pt) 2014-10-14
RU2009140753A (ru) 2011-05-10
CA2681529C (en) 2015-06-30
WO2008122767A3 (en) 2008-12-31
US20100093769A1 (en) 2010-04-15
CN101679434B (zh) 2013-09-25
HK1139939A1 (en) 2010-09-30
RU2461559C2 (ru) 2012-09-20
MX2009010660A (es) 2010-02-17
GB0706632D0 (en) 2007-05-16
JP5466145B2 (ja) 2014-04-09
AU2008235361B2 (en) 2013-02-14
US8592581B2 (en) 2013-11-26
PL2139893T3 (pl) 2013-11-29
WO2008122767A2 (en) 2008-10-16
EP2139893A2 (en) 2010-01-06
EP2139893B1 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
BRPI0809996B8 (pt) compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
BRPI0811280B8 (pt) compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos
AR056320A1 (es) Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos
BR112014007193A2 (pt) derivados de pirazoloquinolinona, preparação dos mesmos e uso terapêutico dos mesmos
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
BR112014011850A2 (pt) derivados de aminopirimidina como moduladores de lrrk2
CL2008002271A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o su sal farmaceutica; proceso de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar un trastorno del sistema nervioso central tal como alzheimer, demencia senil, parkinson.
BR112013020620A2 (pt) análogos de ácido 4-hidroxibutírico
BR112015014333A2 (pt) compostos antivirais
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
BRPI0709773B8 (pt) derivados de malonamida, processo de produção do mesmo, medicamento, e seus usos como inibidores de gama-secretase no tratamento do mal de alzheimer
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
BR112014031969A2 (pt) derivados de pirimidinona como agentes antimaláricos
ECSP088257A (es) Derivados de amida
BR112015022849A2 (pt) sais de adição de base de nitroxolina e usos dos mesmos
ATE543799T1 (de) Piperidinyl- und piperazinylmodulatoren von g- sekretase
BR112018004719A2 (pt) composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto
CL2008003465A1 (es) Compuestos derivados de cicloalquiloxi- y heterocicloalquiloxi- piridina, moduladores del receptor de histamina h3; composicion farmaceutica; y su uso en el tratamiento de trastornos cognitivos, del sueño y psiquiatricos, tales como demencia, enfermedad de alzheimer, deficits cognitivos, insomnio, alteraciones del sueño y depresion.
BR112015016889A8 (pt) derivados de catecolamina enriquecidos com deutério em posição específica
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: CANCER RESEARCH TECHNOLOGY LTD (GB) , CYCLACEL LIM

B25G Requested change of headquarter approved

Owner name: CANCER RESEARCH TECHNOLOGY LTD (GB) , CYCLACEL LIM

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.